BioKin (Baili Tianheng) clinical progress has triggered the next USD250m milestone payment in its collaboration with BMS. The deal revolves around Izabren (Lencon Ilonutumab; BL-B01D1) in oncology. The asset has reached an undisclosed milestone in the IZABRIGHT-Lung02 global Phase 3 study. BioKen is eligible to up to USD7.1bn in future payments contingent on development, registration, and sales milestones.